SG11201805001UA - Method of treating influenza a - Google Patents

Method of treating influenza a

Info

Publication number
SG11201805001UA
SG11201805001UA SG11201805001UA SG11201805001UA SG11201805001UA SG 11201805001U A SG11201805001U A SG 11201805001UA SG 11201805001U A SG11201805001U A SG 11201805001UA SG 11201805001U A SG11201805001U A SG 11201805001UA SG 11201805001U A SG11201805001U A SG 11201805001UA
Authority
SG
Singapore
Prior art keywords
medimmune
gaithersburg
llc
international
way
Prior art date
Application number
SG11201805001UA
Other languages
English (en)
Inventor
Nicole Kallewaard-Lelay
Raburn Mallory
Gabriel Robbie
Song Ren
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201805001UA publication Critical patent/SG11201805001UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
SG11201805001UA 2016-01-13 2017-01-12 Method of treating influenza a SG11201805001UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278068P 2016-01-13 2016-01-13
PCT/US2017/013086 WO2017123685A1 (en) 2016-01-13 2017-01-12 Method of treating influenza a

Publications (1)

Publication Number Publication Date
SG11201805001UA true SG11201805001UA (en) 2018-07-30

Family

ID=59312127

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805001UA SG11201805001UA (en) 2016-01-13 2017-01-12 Method of treating influenza a

Country Status (10)

Country Link
US (3) US20190015509A1 (ja)
EP (1) EP3402513A4 (ja)
JP (3) JP2019502715A (ja)
KR (1) KR20180101436A (ja)
CN (2) CN108697789A (ja)
AU (2) AU2017207330C1 (ja)
CA (1) CA3010313A1 (ja)
IL (2) IL304940A (ja)
SG (1) SG11201805001UA (ja)
WO (1) WO2017123685A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014329609B2 (en) 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
CN107667114B (zh) 2015-06-01 2021-07-02 免疫医疗有限责任公司 中和抗流感结合分子及其用途
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
CN109932350B (zh) * 2019-04-11 2021-06-25 迪佰(厦门)生物科技有限公司 荧光分子、其制备方法和应用、免疫凝聚试剂盒、其制备方法以及检测抗原的方法
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection
EP4021502A1 (en) * 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Compositions and methods for treatment of influenza a infection
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
CN112175075B (zh) * 2020-10-09 2021-08-20 中国人民解放军军事科学院军事医学研究院 一种靶向甲型流感病毒ha蛋白的广谱抗体
WO2023230448A1 (en) * 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU3328900A (en) 1999-03-31 2000-10-23 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
JP4656478B2 (ja) 2000-02-22 2011-03-23 株式会社医学生物学研究所 抗体ライブラリー
CA2490423A1 (en) 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US7175999B2 (en) 2002-07-11 2007-02-13 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
RU2366662C2 (ru) 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
EP1666059A4 (en) 2003-08-11 2008-08-27 Univ Osaka Res Found NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US8343489B2 (en) 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
WO2007117577A2 (en) 2006-04-07 2007-10-18 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-18 receptor
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
PL2059532T3 (pl) 2006-09-07 2013-05-31 Crucell Holland Bv Ludzkie cząsteczki wiążące zdolne do neutralizowania wirusa grypy H5N1 i ich zastosowania
ES2859825T3 (es) 2006-10-02 2021-10-04 Regeneron Pharma Anticuerpos humanos con alta afinidad para el receptor IL-4 humano
WO2008066691A2 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
JP5607620B2 (ja) 2008-07-25 2014-10-15 インスティテュート・フォー・リサーチ・イン・バイオメディシン 抗ａ型インフルエンザウイルス中和抗体およびその使用
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
WO2010054010A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2652496B1 (en) 2010-12-13 2018-01-17 The University of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
ES2608321T3 (es) * 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
PL3418300T3 (pl) * 2011-07-18 2021-05-04 Institute For Research In Biomedicine Neutralizujące przeciwciała przeciwko wirusowi grypy A i ich zastosowania
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2758038B1 (en) 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
US10654915B2 (en) * 2011-12-05 2020-05-19 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
CA2865594C (en) 2012-03-08 2021-07-27 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
TWI657095B (zh) * 2012-11-13 2019-04-21 美商建南德克公司 抗血球凝集素抗體及使用方法
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
AU2014329609B2 (en) * 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
CN107667114B (zh) 2015-06-01 2021-07-02 免疫医疗有限责任公司 中和抗流感结合分子及其用途
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
CA3015347A1 (en) * 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus

Also Published As

Publication number Publication date
AU2021290356A1 (en) 2022-02-03
CN108697789A (zh) 2018-10-23
IL304940A (en) 2023-10-01
US20200397899A1 (en) 2020-12-24
IL260413A (ja) 2018-08-30
JP2024041945A (ja) 2024-03-27
KR20180101436A (ko) 2018-09-12
AU2017207330C1 (en) 2022-06-09
AU2017207330A1 (en) 2018-08-23
CN116271017A (zh) 2023-06-23
AU2017207330B2 (en) 2021-09-23
EP3402513A4 (en) 2019-10-23
US20230181735A1 (en) 2023-06-15
JP2022046574A (ja) 2022-03-23
JP2019502715A (ja) 2019-01-31
US11547756B2 (en) 2023-01-10
IL260413B2 (en) 2024-01-01
US20190015509A1 (en) 2019-01-17
EP3402513A1 (en) 2018-11-21
WO2017123685A1 (en) 2017-07-20
CA3010313A1 (en) 2017-07-20
IL260413B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
SG11201805001UA (en) Method of treating influenza a
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201909949XA (en) Targeted immunotolerance
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805898RA (en) Liquid composition comprising a multistage polymer, its method of preparation and its use
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds